Contrast agents for applications including perfusion imaging

Patent metadata

Field	Value
Publication number	US-9408927-B2
Application number	US-91960009-A
Country	US
Kind code	B2
Filing date	Feb 27, 2009
Priority date	Feb 29, 2008
Publication date	Aug 9, 2016
Grant date	Aug 9, 2016

Abstract

The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-I, and an imaging moiety, and scanning the subject using diagnostic imaging.

First claim

What is claimed is:

1. A method of imaging at least a portion of the central nervous system (CNS) in a subject, comprising:
administering to the subject a contrast agent having a structure as in Formula (II),

wherein:
J is selected from N(R 27 ), S, O, C(═O), C(═O)O, NHCH 2 CH 2 O, a bond, or C(═O)N(R 27 );
K and L, when present, are independently selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, alkyl, heteroaryl, and an imaging moiety, each of which is optionally substituted;
M is selected from alkoxyalkyl or alkyloxy, each of which is optionally substituted, or
L and M, together with the atom to which they are attached, form a ring, optionally substituted;
Q is halo or haloalkyl;
n is 0, 1, 2, or 3;
R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , and R 27 are independently selected from hydrogen, alkyl, optionally substituted, and an imaging moiety;
R 29 is alkyl, optionally substituted; and
Y is carbon or oxygen; provided that when Y is oxygen, K and L are absent and M is alkoxyalkyl, optionally substituted,
wherein at least one imaging moiety is present in Formula (II); and
scanning the subject using diagnostic imaging to produce an image of at least a portion of the CNS.

2. The method as in claim 1 , wherein the method of imaging at least a portion of the CNS in the subject comprises imaging perfusion in the brain of the subject.

3. A method as in claim 1 , wherein the image is used in the diagnosis of a subject.

4. A method as in claim 3 , wherein the diagnosis is a diagnosis of a CNS disorder or condition.

5. A method as in claim 1 , wherein the image is used to determine the stage of a disease.

6. A method as in claim 5 , wherein the disease is a CNS disorder or condition.

7. A method as in claim 1 , further comprising selecting a treatment for a central nervous system (CNS) disorder or condition in the subject based at least in part on the image of at least a portion of the CNS of the subject.

8. A method as in claim 1 , further comprising evaluating a treatment of a central nervous system (CNS) disorder or condition in the subject based at least in part on the image of at least a portion of the CNS of the subject.

9. A method as in claim 2 , further comprising selecting a treatment of a central nervous system (CNS) disorder or condition in the subject based at least in part on the image of at least a portion of the brain.

10. A method as in claim 2 , further comprising evaluating a treatment of a central nervous system (CNS) disorder or condition in the subject based at least in part on the image of at least a portion of the brain.

11. A method as in claim 1 , wherein J is O, Q is Cl, and R 29 is C 1 -C 6 alkyl.

12. A method as in claim 1 , wherein each of K and L is hydrogen, Y is carbon, and M is alkoxyalkyl or alkyloxy, optionally substituted with an imaging moiety.

13. A method as in claim 1 , wherein the imaging moiety is 18 F.

14. A method as in claim 1 , wherein M is alkoxyalkyl or alkyloxy substituted with an imaging moiety.

15. A method as in claim 1 , wherein the contrast agent is:

Assignees

• Robinson Simon P
• Casebier David S
• Yu Ming
• Kagan Mikhail
• Lazewatsky Joel
• Lantheus Medical Imaging Inc

Inventors

• Robinson Simon P
• Casebier David S
• Yu Ming
• Kagan Mikhail
• Lazewatsky Joel

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K51/0459 Primary

  having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine · CPC title